Betaliq
About
Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.
Betaliq is one of 6 Biotechnology companies we track in Tampa Bay — 5% of the region's 130 startups.
Similar companies
View allPsileraBiotechnology | Est. 2019 | TPA | $16M |
Inflammx TherapeuticsBiotechnology | Est. 2020 | TPA | $14M |
Nula TherapeuticsBiotechnology | Est. 2021 | TPA | $7.4M |
Disruption LabsBiotechnology | Est. 2017 | TPA | $3.8M |
Method Testing LabsBiotechnology | Est. 2019 | TPA | $2.5M |
Details
- Region
- Tampa Bay
- City
- Tampa
- Founded
- 2018
- Sector
- Biotechnology
- Website
- betaliq.com
Tampa Bay
Tampa Bay is insurtech, cybersecurity, and defense — anchored by MacDill, a fast-growing St. Pete creative scene, and hands-on hubs like Embarc Collective.